R. Fonseca, P. Bergsagel, J. Drach, J. Shaughnessy, N. Gutierrez et al., International Myeloma Working Group molecular classification of multiple myeloma: spotlight review, Leukemia, vol.91, issue.12, pp.2210-2231, 2009.
DOI : 10.1016/j.beha.2007.08.004

B. Walker, P. Leone, L. Chiecchio, N. Dickens, M. Jenner et al., A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value, Blood, vol.116, issue.15, pp.56-65, 2010.
DOI : 10.1182/blood-2010-04-279596

H. Avet-loiseau, F. Malard, L. Campion, F. Magrangeas, C. Sebban et al., Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?, Blood, vol.117, issue.6, pp.2009-2020, 2011.
DOI : 10.1182/blood-2010-07-295105

I. Hanamura, J. Stewart, Y. Huang, F. Zhan, M. Santra et al., Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation, Blood, vol.108, issue.5, pp.1724-1756, 2006.
DOI : 10.1182/blood-2006-03-009910

P. Liu, T. Leong, L. Quam, D. Billadeau, N. Kay et al., Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial, Blood, vol.88, issue.7, pp.2699-706, 1996.

W. Chng, N. Gonzalez-paz, T. Price-troska, S. Jacobus, S. Rajkumar et al., Clinical and biological significance of RAS mutations in multiple myeloma, Leukemia, vol.21, issue.12, pp.2280-2284, 2008.
DOI : 10.1038/leu.2008.142

J. Keats, R. Fonseca, M. Chesi, R. Schop, A. Baker et al., Promiscuous Mutations Activate the Noncanonical NF-??B Pathway in Multiple Myeloma, Cancer Cell, vol.12, issue.2, pp.131-175, 2007.
DOI : 10.1016/j.ccr.2007.07.003

C. Annunziata, R. Davis, Y. Demchenko, W. Bellamy, A. Gabrea et al., Frequent Engagement of the Classical and Alternative NF-??B Pathways by Diverse Genetic Abnormalities in Multiple Myeloma, Cancer Cell, vol.12, issue.2, pp.115-145, 2007.
DOI : 10.1016/j.ccr.2007.07.004

D. Carrasco, G. Tonon, Y. Huang, Y. Zhang, R. Sinha et al., High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients, Cancer Cell, vol.9, issue.4, pp.313-338, 2006.
DOI : 10.1016/j.ccr.2006.03.019

H. Avet-loiseau, C. Li, F. Magrangeas, W. Gouraud, C. Charbonnel et al., Prognostic Significance of Copy-Number Alterations in Multiple Myeloma, Journal of Clinical Oncology, vol.27, issue.27, pp.4585-90, 2009.
DOI : 10.1200/JCO.2008.20.6136

J. Crawley and K. Furge, Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data, Genome Biol, vol.3, issue.12, p.75, 2002.

T. Santarius, J. Shipley, D. Brewer, M. Stratton, and C. Cooper, A census of amplified and overexpressed human cancer genes, Nature Reviews Cancer, vol.68, issue.1, pp.59-64, 2010.
DOI : 10.1038/nrc2771

P. Futreal, L. Coin, M. Marshall, T. Down, T. Hubbard et al., A census of human cancer genes, Nature Reviews Cancer, vol.4, issue.3, pp.177-83, 2004.
DOI : 10.1038/nrc1299

A. Broyl, D. Hose, H. Lokhorst, Y. De-knegt, J. Peeters et al., Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients, Blood, vol.116, issue.14, pp.2543-53, 2010.
DOI : 10.1182/blood-2009-12-261032

F. Zhan, Y. Huang, S. Colla, J. Stewart, I. Hanamura et al., The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006.
DOI : 10.1182/blood-2005-11-013458

P. Bergsagel and W. Kuehl, Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma, Journal of Clinical Oncology, vol.23, issue.26, pp.6333-6341, 2005.
DOI : 10.1200/JCO.2005.05.021

J. Shaughnessy, J. Zhan, F. Burington, B. Huang, Y. Colla et al., A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, vol.109, issue.6, pp.2276-84, 2007.
DOI : 10.1182/blood-2006-07-038430

O. Decaux, L. Lode, F. Magrangeas, C. Charbonnel, W. Gouraud et al., Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du My??lome, Journal of Clinical Oncology, vol.26, issue.29, pp.4798-805, 2008.
DOI : 10.1200/JCO.2007.13.8545

D. Hose, T. Reme, T. Meissner, J. Moreaux, A. Seckinger et al., Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma, Blood, vol.113, issue.18, pp.4331-4371, 2009.
DOI : 10.1182/blood-2008-09-178350

URL : https://hal.archives-ouvertes.fr/inserm-00368414

A. Seckinger, T. Meissner, J. Moreaux, H. Goldschmidt, G. Fuhler et al., Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis, Oncogene, vol.83, issue.44, pp.3866-79, 2009.
DOI : 10.1182/blood.V99.5.1745

URL : https://hal.archives-ouvertes.fr/inserm-00437705

A. Sprynski, D. Hose, L. Caillot, T. Reme, J. Shaughnessy et al., The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor, Blood, vol.113, issue.19, pp.4614-4640, 2009.
DOI : 10.1182/blood-2008-07-170464

URL : https://hal.archives-ouvertes.fr/inserm-00367812

M. Chesi, P. Bergsagel, L. Brents, C. Smith, D. Gerhard et al., Dys regulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines [see comments], Blood, vol.88, pp.674-81, 1996.

M. Chesi, E. Nardini, R. Lim, K. Smith, W. Kuehl et al., The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts, Blood, vol.92, issue.9, pp.3025-3059, 1998.

R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. Bergsagel et al., Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report, Cancer Research, vol.64, issue.4, pp.1546-58, 2004.
DOI : 10.1158/0008-5472.CAN-03-2876

H. Goldschmidt, P. Sonneveld, F. Cremer, B. Van-der-holt, P. Westveer et al., Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients, Annals of Hematology, vol.82, issue.10, pp.654-663, 2003.
DOI : 10.1007/s00277-003-0685-2

J. Moreaux, B. Klein, R. Bataille, G. Descamps, S. Maiga et al., A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, issue.4, pp.574-82, 2011.
DOI : 10.3324/haematol.2010.033456

URL : https://hal.archives-ouvertes.fr/inserm-00550232

B. Barlogie, G. Tricot, E. Rasmussen, E. Anaissie, F. Van-rhee et al., Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies, Blood, vol.107, issue.7, pp.2633-2641, 2006.
DOI : 10.1182/blood-2005-10-4084

W. Xiong, X. Wu, S. Starnes, S. Johnson, J. Haessler et al., An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma, Blood, vol.112, issue.10, pp.4235-4281, 2008.
DOI : 10.1182/blood-2007-10-119123

P. Shannon, A. Markiel, O. Ozier, N. Baliga, J. Wang et al., Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks, Genome Research, vol.13, issue.11
DOI : 10.1101/gr.1239303

K. Neben, A. Jauch, U. Bertsch, C. Heiss, T. Hielscher et al., Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation, Haematologica, vol.95, issue.7, pp.1150-1157, 2010.
DOI : 10.3324/haematol.2009.016436

S. Popp, A. Jauch, D. Schindler, M. Speicher, C. Lengauer et al., A strategy for the characterization of minute chromosome rearrangements using multiple color fluorescence in situ hybridization with chromosome-specific DNA libraries and YAC clones, Human Genetics, vol.19, issue.6, pp.527-559, 1993.
DOI : 10.1007/BF00420933

F. Cremer, J. Bila, I. Buck, M. Kartal, D. Hose et al., Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics, Genes, Chromosomes and Cancer, vol.40, issue.2, pp.194-203, 2005.
DOI : 10.1002/gcc.20231

D. Hose, J. Rossi, C. Ittrich, J. Devos, A. Benner et al., A New molecular classification of multiple myeloma using gene expression profiling and fluorescence in situ hybridisation as predictor for event free survival, Blood, vol.104, issue.11, p.73, 2004.

S. Wuilleme, N. Robillard, L. Lode, F. Magrangeas, H. Beris et al., Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma, Leukemia, vol.19, issue.2, pp.275-283, 2005.
DOI : 10.1038/sj.leu.2403586

P. Rao, J. Cigudosa, Y. Ning, M. Calasanz, S. Iida et al., Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma, Blood, vol.92, issue.5, pp.1743-1751, 1998.

E. Schrock, S. Du-manoir, T. Veldman, B. Schoell, J. Wienberg et al., Multicolor Spectral Karyotyping of Human Chromosomes, Science, vol.273, issue.5274, pp.494-501, 1996.
DOI : 10.1126/science.273.5274.494

J. Sawyer, J. Lukacs, N. Munshi, K. Desikan, S. Singhal et al., Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping, Blood, vol.92, issue.11, pp.4269-78, 1998.

H. Telenius, A. Pelmear, A. Tunnacliffe, N. Carter, A. Behmel et al., Cytogenetic analysis by chromosome painting using dop-pcr amplified flow-sorted chromosomes, Genes, Chromosomes and Cancer, vol.78, issue.3, pp.257-63, 1992.
DOI : 10.1002/gcc.2870040311

L. Shaffer and . Tn, An International System for Human Cytogenetic Nomenclature, 2005.

T. Reme, D. Hose, D. Vos, J. Vassal, A. Poulain et al., A new method for class prediction based on signed-rank algorithms applied to Affymetrix?? microarray experiments, BMC Bioinformatics, vol.9, issue.1, p.16, 2008.
DOI : 10.1186/1471-2105-9-16

URL : https://hal.archives-ouvertes.fr/inserm-00268075

S. Assou, L. Carrour, T. Tondeur, S. Strom, S. Gabelle et al., A Meta-Analysis of Human Embryonic Stem Cells Transcriptome Integrated into a Web-Based Expression Atlas, Stem Cells, vol.22, issue.4, pp.961-73, 2007.
DOI : 10.1634/stemcells.2006-0352

URL : https://hal.archives-ouvertes.fr/inserm-00128925

R. Team, R: A Language and Environ ment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.

R. Gentleman, V. Carey, D. Bates, B. Bolstad, M. Dettling et al., Bioconductor: open software development for computational biology and bioinformatics, Genome Biology, vol.5, issue.10, p.80, 2004.
DOI : 10.1186/gb-2004-5-10-r80

D. Hose, J. Devos, N. Muller, J. Rossi, C. Heib et al., Clonal and subclonal cytogenetic aberrations: association with D-type cyclin expression and event-free survival (EFS) in multiple myeloma (MM), Blood, vol.108, issue.11, p.982, 2006.

D. Hose, T. Reme, T. Hielscher, J. Moreaux, T. Meissner et al., Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma, Haematologica, vol.96, issue.1, pp.87-95, 2011.
DOI : 10.3324/haematol.2010.030296

D. Hose, T. Reme, T. Hielscher, J. Moreaux, T. Meissner et al., B034 A Gene Expression???Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma, Clinical Lymphoma and Myeloma, vol.9, issue.11, p.589, 2008.
DOI : 10.1016/S1557-9190(11)70649-7